Table 2.
Demographic and baseline characteristics of participants by long-term cardiovascular mortality
| No events (n = 9,433) | Events (n = 59) | P value | |
|---|---|---|---|
| Age (years) | 47.00 (32.00–61.00) | 74.00 (67.50–80.00) | < 0.001 |
| Age group | |||
| < 65 years | 7593 (80.49%) | 14 (23.73%) | < 0.001 |
| ≥ 65 years | 1840 (19.51%) | 45 (76.27%) | |
| Sex | |||
| Male | 4542 (48.15%) | 43 (72.88%) | < 0.001 |
| Female | 4891 (51.85%) | 16 (27.12%) | |
| Race | |||
| Mexican American | 1605 (17.01%) | 10 (16.95%) | 0.069 |
| Non-Hispanic white | 1105 (11.71%) | 9 (15.25%) | |
| Non-Hispanic black | 2926 (31.02%) | 25 (42.37%) | |
| Other Hispanic | 2083 (22.08%) | 12 (20.34%) | |
| Other races | 1714 (18.17%) | 3 (5.08%) | |
| Drinking | 4452 (47.20%) | 21 (35.59%) | 0.075 |
| Smoking | 3717 (39.40%) | 30 (50.85%) | 0.073 |
| Hypertension | 3162 (33.52%) | 40 (67.80%) | < 0.001 |
| Diabetes | 1305 (13.83%) | 27 (45.76%) | < 0.001 |
| Heart failure | 264 (2.80%) | 22 (37.29%) | < 0.001 |
| CAD | 314 (3.33%) | 17 (28.81%) | < 0.001 |
| Stroke | 329 (3.49%) | 7 (11.86%) | < 0.001 |
| Lipid-lowering drugs | 1659 (17.59%) | 27 (45.76%) | < 0.001 |
| BMI (kg/m2) | 28.40 (24.50–33.40) | 29.10 (25.30–32.20) | 0.796 |
| Hs-CRP (mg/L) | 1.90 (0.80–4.50) | 2.85 (1.25–6.06) | 0.010 |
| HDL-C (mmol/L) | 1.32 (1.09–1.60) | 1.22 (0.94–1.47) | 0.006 |
| HDL-C (mg/L) | 5.10 (4.22–6.19) | 4.72 (3.62–5.68) | |
| Hs-CRP/HDL-C ratio | 0.37 (0.14–0.95) | 0.60 (0.23–1.60) | 0.002 |
Data were presented as median (Q1-Q3) or N (%). CAD, coronary artery disease; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; Divide HDL-C (mmol/L) by 0.2586 to convert to mg/L